SRPT Stock Surges on Promising Early Results From siRNA Programs [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
data on two experimental siRNA therapies, which were acquired last year as part of a licensing deal with Arrowhead Pharmaceuticals. Sarepta unveiled the first clinical results from two ongoing phase I/II studies — one evaluating SRP-1001 for facioscapulohumeral muscular dystrophy type I (FSHD1) and another evaluating SRP-1003 for myotonic dystrophy type I (DM1). The data showed that both drugs achieved high muscle concentrations without dose-limiting toxicity in patients with FSHD1 or DM1. More Details on SRPT's Phase I/II Studies Early clinical data on both studies showed that after a single dose, SRP-1001 and SRP-1003 supported the reduction of the target protein (or mRNA). The initial data also demonstrated dose-dependent muscle delivery, early biomarker activity and favorable safety profiles. With regard to SRP-1001, data showed that a single dose achieved significantly higher muscle siRNA levels versus prior approaches and led to robust pharmacodynamic effects, including
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead [Seeking Alpha]Seeking Alpha
- Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals (ARWR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Abselion Appoints Dale Gordon as Chair [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 3/9/26 - Form 4
- ARWR's page on the SEC website